• Latest Posts

The Largest Deals, Fundraising and Exits of 2016 in European Biotech

BMS Offers €850M for a British Oncolytic Virus better than CAR-T

Microbiomics recruited for Immuno-Oncology in a Huge New Partnership

Results from 45% of Clinical Trials are kept Secret

It’s not over yet for Opdivo; AbbVie takes a stand in Leukemia

Big Pharmas Battle to be the Lung Cancer Leader at ESMO


BMS to acquire Swedish Immuno-Oncology Biotech for €460M

BMS to combine Immuno-Oncology Blockbuster with Oxford Biotech

New Massive €250M Investment Fund Closed for European Biotech

A French Biotech is Monopolising Immuno-Oncology with Big Euro Deals

Money Money Money for Immuno-Oncology: BMS Joins up with a Top German VC

Innate Pharma receives $5M from its Monster-deal with BMS